November 1994

Safety and Immunogenicity of a Five-Component Acellular Pertussis Vaccine With Varying Antigen Quantities

Author Affiliations

Departments of Pediatrics and Microbiology Dalhousie University 5850 University Ave Halifax, Nova Scotia, Canada B3J 3G9
Willowdale, Ontario
Winnipeg, Manitoba
Calgary, Alberta

Arch Pediatr Adolesc Med. 1994;148(11):1220-1224. doi:10.1001/archpedi.1994.02170110106025

Since its introduction 50 years ago, whole-cell pertussis vaccines have successfully controlled pertussis in North America. Although outbreaks continue to occur, the reported incidence of pertussis has fallen by over 90% in Canada and the United States.1,2 Despite this success, the frequency of adverse reactions has spurred efforts to develop a less reactogenic product.3 Acellular vaccines that contain purified antigens of Bordetella pertussis cause fewer adverse reactions and have been approved for use in the United States for booster doses.4 Most acellular pertussis vaccines contain pertussis toxoid (PT) and filamentous hemagglutinin (FHA); other antigens considered for inclusion are fimbriae (agglutinogens 2 and 3) and a 69-kd membrane protein (pertactin). Acellular vaccines have been developed that include the 69-kd protein with PT and FHA,5 fimbriae with PT and FHA,6 and that contain PT, FHA, fimbriae, and the 69-kd protein in fixed quantities as a result of

First Page Preview View Large
First page PDF preview
First page PDF preview